Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Format:	Journal article
Język:	English
Wydane:	Elsevier 2020

Podobne zapisy

Lipid-modifying agents, from statins to PCSK9 inhibitors
od: Preiss, D, i wsp.
Wydane: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
od: Sanjiv Gupta
Wydane: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
od: Caleyachetty, R, i wsp.
Wydane: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
od: K. O. Shnaider, i wsp.
Wydane: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
od: Konstantinos Koskinas, i wsp.
Wydane: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
od: Christopher LaFratte, i wsp.
Wydane: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
od: Nissen, SE, i wsp.
Wydane: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
od: Mohsin Haseeb, i wsp.
Wydane: (2023-03-01)

JACC: Asia
od: Jian'an Wang, MD, PhD
Wydane: (2021-06-01)

JACC: Asia
od: Valentin Fuster, MD, PhD, i wsp.
Wydane: (2021-06-01)

The PCSK9 decade
od: Gilles Lambert, i wsp.
Wydane: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
od: Mbikay Majambu, i wsp.
Wydane: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
od: Shuai Wang, i wsp.
Wydane: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
od: Ying Xiao, i wsp.
Wydane: (2022-11-01)

PCSK9 inhibitors
od: Baris Gencer, i wsp.
Wydane: (2015-04-01)

JACC: Case Reports
od: Julia Grapsa, MD, PhD, i wsp.
Wydane: (2019-08-01)

JACC: Case Reports
od: Julia Grapsa, MD, PhD, i wsp.
Wydane: (2020-06-01)

JACC: Case Reports
od: Purvi Parwani, MBBS, MPH, i wsp.
Wydane: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
od: Preiss, D, i wsp.
Wydane: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
od: Maram H. Abduljabbar
Wydane: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
od: Sliz, E, i wsp.
Wydane: (2018)

Vision for JACC: Case Reports
od: Julia Grapsa, MD, PhD
Wydane: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
od: Armitage, J, i wsp.
Wydane: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
od: A. V. Blokhina, i wsp.
Wydane: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
od: Markus Mohaupt
Wydane: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
od: Bijay Mukesh Jeswani, i wsp.
Wydane: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
od: Naoto Kuyama, i wsp.
Wydane: (2021-06-01)

Introducing JACC: Basic to Translational Science
od: Douglas L. Mann, MD, i wsp.
Wydane: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
od: Weiqi Zeng, i wsp.
Wydane: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
od: Preiss, D, i wsp.
Wydane: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
od: Dennis T. Ko, i wsp.
Wydane: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
od: Tiny Nair
Wydane: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
od: Martin Jozef Péč, i wsp.
Wydane: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
od: Caroline Coppinger BS, i wsp.
Wydane: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
od: L. Castilla-Guerra, i wsp.
Wydane: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
od: A. Yu. Filatova, i wsp.
Wydane: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
od: Marianna Puccini, i wsp.
Wydane: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
od: Blom DJ, i wsp.
Wydane: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
od: Zinan ZHAO, i wsp.
Wydane: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
od: Lillian Smith, i wsp.
Wydane: (2016-03-01)